{"id":576538,"date":"2026-08-06T12:46:12","date_gmt":"2026-08-06T12:46:12","guid":{"rendered":"https:\/\/www.newsbeep.com\/il\/576538\/"},"modified":"2026-08-06T12:46:12","modified_gmt":"2026-08-06T12:46:12","slug":"oral-cholesterol-lowering-peptide-approved-after-a-decade-in-development-business","status":"publish","type":"post","link":"https:\/\/www.newsbeep.com\/il\/576538\/","title":{"rendered":"Oral cholesterol-lowering peptide approved after a decade in development | Business"},"content":{"rendered":"<p>The US Food and Drug Administration (FDA) has <a href=\"https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-oral-pcsk9-inhibitor-lower-ldl-cholesterol-adults-high-cholesterol\" rel=\"nofollow noopener\" target=\"_blank\">approved Merck &amp; Co\u2019s Lipfendra (enlicitide)<\/a> to reduce levels of \u2018bad\u2019 low-density lipoprotein\u2013cholesterol (LDL-C). The macrocyclic peptide is the first oral inhibitor of <a href=\"https:\/\/en.wikipedia.org\/wiki\/PCSK9\" rel=\"nofollow noopener\" target=\"_blank\">PCSK9<\/a>, and offers an alternative to injected antibodies when standard statin treatment hasn\u2019t lowered patients\u2019 LDL-C enough.<\/p>\n<p>Enlicitide has been in development for a decade, explains David Thaisrivongs, Merck executive director head of biocatalysis, who says \u2018it\u2019s been long time coming\u2019 after the success of PCSK9 injectables. Regeneron\u2019s Praluent (alirocumab) and Amgen\u2019s Repatha (evolocumab), which target the same enzyme, have both been on the market since 2015.<\/p>\n<p class=\"picture\"><img decoding=\"async\" alt=\"Enlicitide\" src=\"https:\/\/d2cbg94ubxgsnp.cloudfront.net\/Pictures\/web\/v\/z\/z\/enlicitide_937174.svgz\" loading=\"eager\" class=\"lazyloaded\"\/><\/p>\n<p>\u2018Despite the tremendous progress in the treatment of cardiovascular disease, it remains the number one cause of death worldwide. I\u2019m super proud of the science [of enlicitide] but seeing the real-world impact \u2013 I just get goosebumps thinking about what this could mean for so many people,\u2019 says Thaisrivongs.<\/p>\n<p>The interactions between PCSK9 and the LDL proteins are very difficult to influence using small molecules. Thraisivongs says that enlicitide shows \u2018it\u2019s possible to use a macrocyclic peptide to do what a traditional small molecule couldn\u2019t\u2019. Designing enlicitide involved introducing molecular complexity that created a \u2018massive chemistry challenge\u2019, says Thaisrivongs, who faced serious doubts over whether this larger molecule could be manufactured in a way that would be \u2018viable in the marketplace\u2019.<\/p>\n<p>\u2018Our goal was always to develop the most potent and accessible cholesterol-lowering pill. Many companies including Merck tried to develop a small molecule but weren\u2019t successful,\u2019 he explains. The Merck team took a different approach, developing a macrocyclic peptide that can be \u2018delivered orally like a small molecule but is large enough to interact in-between PCSK9 and the LDL receptor.\u2019<\/p>\n<p>He says there were a couple of \u2018pivotal moments\u2019 in the discovery of enlicitide, including the phase 1 studies finding it could be orally absorbed \u2013 providing that first \u2018promise of a pill therapy\u2019. He adds that an \u2018incredible innovation\u2019 came from the medicinal chemistry team\u2019s recognition, based on crystal structure data, that the molecule\u2019s potency and stability could be enhanced with key chemical cross-links. \u2018Those cross-links provide the exquisite properties of enlicitide that allow it to function [more like an] antibody,\u2019 he explains.<\/p>\n<p class=\"picture\"><img decoding=\"async\" alt=\"Enlicitide (Lipfendra) pills and bottle\" src=\"https:\/\/www.newsbeep.com\/il\/wp-content\/uploads\/2026\/08\/550515_lipfendra_2b_bottle_pill_709060.jpg\"  loading=\"lazy\" class=\"lazyloaded\" width=\"1280\" height=\"720\"\/><\/p>\n<p>In the end, the team developed a <a href=\"https:\/\/doi.org\/10.1021\/jacs.4c15966\" rel=\"nofollow noopener\" target=\"_blank\">biocatalytic synthesis that employs 13 different engineered enzymes<\/a>, which enabled simultaneous reactions without the need for protection and deprotection reactions to avoid cross-reactivity, greatly improving efficiency. \u2018There\u2019s been an incredible sea change in the way that we think about working on molecules. It\u2019s important to appreciate that 15\u201320 years ago, this was a really crazy idea for chemists,\u2019 Thaisrivongs says.<\/p>\n<p>\u2018The kinds of molecules that are being discovered and evaluated clinically these days are so much more diverse from when I started my career,\u2019 he adds. \u2018There\u2019s so many interesting, weird and wonderful molecules that fall somewhere in between the extremes [of large and small molecules] and enlicitide is one example. To bring the promise of these new types of molecules to patient impact, we need to be able to make them in a way that provides for accessibility.\u2019<\/p>\n<p>Because enlicitide is a peptide, to ensure it survives the stomach, patients must take it on an empty stomach and not eat or drink for 30 minutes afterwards for it to be fully effective. Preventative cardiologist Michael Shapiro, whose work at Wake Forest university, US includes investigating PCSK9 physiology, says this is unlikely to be much of a barrier.<\/p>\n<p>\u2018There\u2019s lots of very common drugs that require fasting so that\u2019s not really a big deal in my mind,\u2019 he says. \u2018What\u2019s very exciting is it seems to [be just as effective] as the injectable drugs.\u2019 He explains that PCSK9 antibodies are mostly prescribed by specialist doctors, whereas oral drugs might be more likely to be an option that general practitioners would prescribe, making them more easily accessible to more patients. \u2018The cost will still be an issue,\u2019 he says, \u2018but in the future when it\u2019s generic, it will be inexpensive.\u2019<\/p>\n<p>However, looking to the future of heart health, Shapiro says it goes far beyond individual medicines, bringing whole-system shifts towards prevention. He hopes to one day see an annual or even once-in-a-lifetime heart attack prevention treatment. \u2018Things are dramatically changing \u2013 some of which is obviously years away but it\u2019s very likely to come to fruition. Enlicitide is certainly an exciting development, but the landscape of cholesterol therapies, this is incremental compared to much more innovative approaches.\u2019<\/p>\n<p>He points out that huge numbers of deaths from cardiovascular disease should be preventable. \u2018The problem is implementation, cost, adherence, and many other practical, logistical considerations. Enlicitide will help a group of patients \u2013 which is great \u2013 but it won\u2019t solve the larger problem we have.\u2019<\/p>\n","protected":false},"excerpt":{"rendered":"The US Food and Drug Administration (FDA) has approved Merck &amp; Co\u2019s Lipfendra (enlicitide) to reduce levels of&hellip;\n","protected":false},"author":2,"featured_media":576539,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[10],"tags":[163,85,46],"class_list":["post-576538","post","type-post","status-publish","format-standard","has-post-thumbnail","category-health","tag-health","tag-il","tag-israel"],"_links":{"self":[{"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/posts\/576538","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/comments?post=576538"}],"version-history":[{"count":0,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/posts\/576538\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/media\/576539"}],"wp:attachment":[{"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/media?parent=576538"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/categories?post=576538"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/tags?post=576538"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}